Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Bariatric Surgery in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Long-Term Benefits for Liver Health.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Juárez-Sosa José M, Uribe Misael, Montalvo-Javé Eduardo E, Nuño-Lámbarri Natalia
Аннотация
OBJECTIVE: To review the physiological, hormonal, and molecular mechanisms through which bariatric surgery-particularly sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB)-modifies liver disease progression in metabolic dysfunction-associated steatotic liver disease (MASLD).
METHODS: A narrative review of current literature examining clinical outcomes, mechanistic pathways, and long-term hepatic and cardiometabolic effects of SG and RYGB in patients with MASLD.
RESULTS: Both SG and RYGB induce sustained weight loss and durable metabolic improvements. Beyond caloric restriction, these procedures promote significant alterations in gut hormones, bile acid signaling, insulin sensitivity, systemic inflammation, and adipose-liver crosstalk. Clinical evidence demonstrates marked reductions in hepatic steatosis and inflammation, with partial fibrosis regression in selected patients. Bariatric surgery is also associated with decreased incidence of cirrhosis, hepatocellular carcinoma, cardiovascular events, and improved overall survival and quality of life.
CONCLUSION: Bariatric surgery represents a disease-modifying intervention in MASLD, exerting metabolic and hepatic benefits that extend beyond weight reduction. It should be considered an integral component of multidisciplinary management, particularly in patients with obesity and high cardiometabolic risk.
METHODS: A narrative review of current literature examining clinical outcomes, mechanistic pathways, and long-term hepatic and cardiometabolic effects of SG and RYGB in patients with MASLD.
RESULTS: Both SG and RYGB induce sustained weight loss and durable metabolic improvements. Beyond caloric restriction, these procedures promote significant alterations in gut hormones, bile acid signaling, insulin sensitivity, systemic inflammation, and adipose-liver crosstalk. Clinical evidence demonstrates marked reductions in hepatic steatosis and inflammation, with partial fibrosis regression in selected patients. Bariatric surgery is also associated with decreased incidence of cirrhosis, hepatocellular carcinoma, cardiovascular events, and improved overall survival and quality of life.
CONCLUSION: Bariatric surgery represents a disease-modifying intervention in MASLD, exerting metabolic and hepatic benefits that extend beyond weight reduction. It should be considered an integral component of multidisciplinary management, particularly in patients with obesity and high cardiometabolic risk.